Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present DBV Technologies S.A. (NASDAQ: DBVT).

Full DD Report for DBVT

You must become a subscriber to view this report.


Recent News from (NASDAQ: DBVT)

DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors
DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Michel de Rosen has been appointed to the Company's B...
Source: Thomson Reuters ONE
Date: May, 16 2018 01:30
DBV Technologies Partners with FARE to Help Raise Awareness of Food Allergies in Support of the 21st Anniversary of Food Allergy Awareness Week
DBV Technologies Partners with FARE to Help Raise Awareness of Food Allergies in Support of the 21 st Anniversary of Food Allergy Awareness Week DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, is supp...
Source: Thomson Reuters ONE
Date: May, 14 2018 08:31
DBV Technologies to Present New Clinical Data from Viaskin Platform at the 2018 EAACI Meeting
DBV Technologies to Present New Clinical Data from Viaskin Platform at the 2018 EAACI Meeting Results from positive Phase II study of second product candidate, Viaskin Milk, to be presented as a late breaking oral abstract Seven abstracts accepted, including additional data fro...
Source: Thomson Reuters ONE
Date: May, 08 2018 01:30
DBV Technologies Reports March 31, 2018 Cash Position
DBV Technologies Reports March 31, 2018 Cash Position DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced its cash and cash equivalents as of March 31, 2018. Cash and cash equivalents: Cash and cash equivalents as of March 31, 2018,...
Source: Thomson Reuters ONE
Date: April, 27 2018 01:30
Investor Expectations to Drive Momentum within Criteo S.A, Prima BioMed, CoStar Group, DBV Technologies S.A, Hollysys Automation Technologies, and China Biologic Products - Discovering Underlying Factors of Influence
NEW YORK, April 13, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Criteo S.A. (NASDAQ:CRTO), Immutep Limited (NASDAQ:IMMP), CoStar Group, ...
Source: GlobeNewswire
Date: April, 13 2018 07:45
DBV Technologies to Attend the 11th Kempen Life Sciences Conference
DBV Technologies to Attend the 11 th Kempen Life Sciences Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that Susanna Mesa, Chief Business Officer, will host investor meetings during the 11 th Kempen Life Sciences Con...
Source: Thomson Reuters ONE
Date: April, 03 2018 01:30
Institutional Top Ideas Series: Deerfield Management
In the first entry of this recently rebooted series, we took a look at top ideas from Consonance Capital (whose performance almost tripled that of the IBB during time frame we looked at). Keep in mind articles older than 10 days can only be accessed if you have a membership to ROTY or Se...
Source: SeekingAlpha
Date: March, 28 2018 18:55
DBV Technologies Announces Closing of Underwriters' Option to Purchase Additional Shares in Global Offering
DBV Technologies Announces Closing of Underwriters' Option to Purchase Additional Shares in Global Offering DBV Technologies (the "Company") (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the issuance and t...
Source: Thomson Reuters ONE
Date: March, 26 2018 16:01
DBV Technologies Announces Closing of Global Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
DBV Technologies Announces Closing of Global Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares DBV Technologies (the "Company") (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced ...
Source: Thomson Reuters ONE
Date: March, 23 2018 16:01
DBV Technologies Announces Pricing of $150.0 million (Euro122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
DBV Technologies Announces Pricing of $150.0 million ( € 122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the "Company") (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage ...
Source: Thomson Reuters ONE
Date: March, 21 2018 03:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1725.1624.7925.2624.7388,695
2017-02-0333.6033.4233.8233.40274,517
2017-02-0234.1933.9334.4733.9335,750
2017-02-0134.1634.4534.4534.0342,799
2017-01-3133.8034.5234.62233.26138,186

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1715,47338,64840.0357Short
2018-08-1631,38055,76356.2739Short
2018-08-1547,866112,47142.5585Short
2018-08-1414,63625,49157.4163Short
2018-08-1313,39724,39754.9125Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DBVT.


About DBV Technologies S.A. (NASDAQ: DBVT)

Logo for DBV Technologies S.A. (NASDAQ: DBVT)

Not available

 

Contact Information

 

 

Current Share Structure

  • Issue and Outstanding: 49,981,644 - 12/31/2017

 


Recent Filings from (NASDAQ: DBVT)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 16 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 14 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 08 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: May, 07 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: April, 12 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 03 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 26 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 23 2018

 

 


Daily Technical Chart for (NASDAQ: DBVT)

Daily Technical Chart for (NASDAQ: DBVT)


Stay tuned for daily updates and more on (NASDAQ: DBVT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: DBVT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DBVT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of DBVT and does not buy, sell, or trade any shares of DBVT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/